InfuSystem Holdings, Inc Goodwill & Intangibles Disclosure
| Device Solutions (a) | ||||||||
| Balance as of December 31, 2024 | 3,710 | |||||||
| Goodwill acquired | — | |||||||
| Balance as of December 31, 2025 | $ | 3,710 | ||||||
(a) The Patient Services segment has no recorded goodwill. | ||||||||
| December 31, 2025 | December 31, 2024 | ||||||||||||||||||||||||||||||||||
| Gross Assets | Accumulated Amortization | Net | Gross Assets | Accumulated Amortization | Net | ||||||||||||||||||||||||||||||
| Nonamortizable intangible assets | |||||||||||||||||||||||||||||||||||
Trade names | $ | 2,000 | $ | — | $ | 2,000 | $ | 2,000 | $ | — | $ | 2,000 | |||||||||||||||||||||||
| Amortizable intangible assets | |||||||||||||||||||||||||||||||||||
Trade names | 23 | (23) | — | 23 | (23) | — | |||||||||||||||||||||||||||||
Physician and customer relationships | 40,164 | (35,627) | 4,537 | 38,834 | (34,996) | 3,838 | |||||||||||||||||||||||||||||
| Unpatented technology | 943 | (662) | 281 | 943 | (528) | 415 | |||||||||||||||||||||||||||||
| Non-competition agreements | 472 | (444) | 28 | 472 | (349) | 123 | |||||||||||||||||||||||||||||
Software | 10,300 | (10,280) | 20 | 10,300 | (10,220) | 80 | |||||||||||||||||||||||||||||
Total nonamortizable and amortizable intangible assets | $ | 53,902 | $ | (47,036) | $ | 6,866 | $ | 52,572 | $ | (46,116) | $ | 6,456 | |||||||||||||||||||||||
| 2026 | 2027 | 2028 | 2029 | 2030 | 2031 and thereafter | ||||||||||||||||||||||||||||||
Amortization expense | $ | 715 | $ | 661 | $ | 538 | $ | 527 | $ | 527 | $ | 1,898 | |||||||||||||||||||||||
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Feb 27, 2026 | Showing above |
| 2024 | Mar 11, 2025 | |
| 2023 | Apr 10, 2024 | |
| 2022 | Mar 16, 2023 | |
| 2021 | Mar 15, 2022 | |
| 2020 | Mar 22, 2021 | |
| 2019 | Mar 30, 2020 | |
| 2018 | Mar 22, 2019 | |
| 2017 | Mar 19, 2018 | |
| 2016 | Mar 22, 2017 | |
| 2015 | Mar 9, 2016 | |
About Goodwill & Intangibles Disclosures
Goodwill and intangible asset disclosures reveal the premium paid in acquisitions and how management assesses whether that premium retains its value. Since goodwill is no longer amortized under US GAAP, the annual impairment test is the only mechanism that adjusts carrying values downward — making the assumptions behind that test critically important for investors.
Key signals: a history of goodwill impairments suggests management consistently overpays for acquisitions. Watch the gap between reporting unit fair value and carrying amount — when fair value exceeds carrying amount by less than 10-20%, a small decline in business performance could trigger a write-down. For finite-lived intangibles, examine useful life assumptions across customer relationships, technology, and trade names; aggressive estimates inflate near-term earnings. Compare total intangibles-to-total-assets ratios against peers to assess acquisition dependency. Rising goodwill as a percentage of equity can signal balance sheet fragility.